CORD-19:932bcdd2f6c6d487386e8bf983e4874387771be1 / 284352-284608 JSONTXT

{"project":"CORD-19-Sentences","denotations":[{"id":"T16114","span":{"begin":0,"end":256},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"EAE was produced in 8-9 weeks old female C57BL/6 mice via immunization with myelin oligodendrocyte glycoprotein and animals were sacrificed either at the initiation of disease, at the ascending phase of disease, at peak disease, and at score stabilization."}

{"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T361","span":{"begin":0,"end":256},"obj":"Sentence"}],"text":"EAE was produced in 8-9 weeks old female C57BL/6 mice via immunization with myelin oligodendrocyte glycoprotein and animals were sacrificed either at the initiation of disease, at the ascending phase of disease, at peak disease, and at score stabilization."}

{"project":"CORD-19-PD-HP","denotations":[{"id":"T488","span":{"begin":0,"end":3},"obj":"Phenotype"}],"attributes":[{"id":"A488","pred":"hp_id","subj":"T488","obj":"http://purl.obolibrary.org/obo/HP_0002383"}],"text":"EAE was produced in 8-9 weeks old female C57BL/6 mice via immunization with myelin oligodendrocyte glycoprotein and animals were sacrificed either at the initiation of disease, at the ascending phase of disease, at peak disease, and at score stabilization."}

{"project":"CORD-19-PD-UBERON","denotations":[{"id":"T862","span":{"begin":76,"end":82},"obj":"Body_part"}],"attributes":[{"id":"A862","pred":"uberon_id","subj":"T862","obj":"http://purl.obolibrary.org/obo/UBERON_0000345"}],"text":"EAE was produced in 8-9 weeks old female C57BL/6 mice via immunization with myelin oligodendrocyte glycoprotein and animals were sacrificed either at the initiation of disease, at the ascending phase of disease, at peak disease, and at score stabilization."}

{"project":"CORD-19-PD-MONDO","denotations":[{"id":"T1703","span":{"begin":0,"end":3},"obj":"Disease"},{"id":"T56498","span":{"begin":0,"end":3},"obj":"Disease"}],"attributes":[{"id":"A1703","pred":"mondo_id","subj":"T1703","obj":"http://purl.obolibrary.org/obo/MONDO_0005156"},{"id":"A1704","pred":"mondo_id","subj":"T1703","obj":"http://purl.obolibrary.org/obo/MONDO_0019956"},{"id":"A1705","pred":"mondo_id","subj":"T1703","obj":"http://purl.obolibrary.org/obo/MONDO_0005134"},{"id":"A14619","pred":"mondo_id","subj":"T56498","obj":"http://purl.obolibrary.org/obo/MONDO_0005156"},{"id":"A30424","pred":"mondo_id","subj":"T56498","obj":"http://purl.obolibrary.org/obo/MONDO_0019956"},{"id":"A6869","pred":"mondo_id","subj":"T56498","obj":"http://purl.obolibrary.org/obo/MONDO_0005134"}],"text":"EAE was produced in 8-9 weeks old female C57BL/6 mice via immunization with myelin oligodendrocyte glycoprotein and animals were sacrificed either at the initiation of disease, at the ascending phase of disease, at peak disease, and at score stabilization."}